AcuityMD Raises $80M to Integrate AI in Medical Device Commercial Platform
Brief news summary
AcuityMD has raised $80 million in funding to enhance its platform with AI features for medical device commercial teams. Founded in 2019, the company has now secured $160 million in total, serving 16 of the top 20 medtech firms. Its software integrates external data like FDA records with internal company information to aid commercial decision-making. The platform includes AcuityAI, an AI tool in open beta that helps sales reps and leaders streamline tasks such as planning customer visits and preparing meetings, enabling creation of detailed business plans and optimized itineraries focused on high-value targets. Valued at $955 million after this round, AcuityMD plans to expand AI capabilities across commercial roles, deepen data aggregation, and extend its platform beyond commercialization. Ultimately, AcuityMD aims to accelerate medical technology adoption across the product life cycle by improving how commercial teams utilize data for better outcomes.This audio is auto-generated. Please share any feedback you may have. Dive Brief: AcuityMD has secured $80 million in funding to enhance its platform for medical device commercial teams by incorporating artificial intelligence features. Announced Tuesday, the company offers a platform that integrates third-party data—such as Food and Drug Administration records—relevant to commercial teams. It aligns this external data with a company’s internal information to support informed commercial decision-making. AcuityMD has developed an AI tool designed to assist teams in utilizing this data more effectively, for instance by reducing the time a sales representative needs to plan a day of visits to customers and prospects. Dive Insight: According to the software provider, AcuityMD serves 16 of the top 20 medtech companies. Since its establishment in 2019, the company has raised a total of $160 million. This most recent funding round has valued the company at $955 million. The new capital will be used to introduce agentic AI capabilities tailored for commercial roles, including sales representatives, leadership, and marketing teams. Additional goals include enhancing the platform’s data aggregation and extending its scope beyond commercialization.
AcuityMD describes this growth as part of its mission to accelerate medical technology adoption throughout the product life cycle. AcuityAI, an AI tool, is currently available in open beta. Mark Edwards, senior director of sales operations at Kuros Biosciences, a bone graft company, described how one of his colleagues utilized the tool to analyze the data platform. “One of our sales leaders requested AcuityAI for insights on a new national contract with a major health system and quickly received a comprehensive business plan: where to visit, which surgeons to prioritize, and far more context than spending hours researching on Google, ” Edwards said in a statement. AcuityMD also shared a video illustrating another scenario, where a sales representative asked AcuityAI to organize their day. The user requested prioritization of high-value targets to boost device adoption. In response, the tool created an itinerary including a driving route, factoring in the rep’s existing appointments and the schedules of pertinent healthcare providers. Additionally, the tool can assist representatives in preparing for individual meetings.
Watch video about
AcuityMD Raises $80M to Integrate AI in Medical Device Commercial Platform
Try our premium solution and start getting clients — at no cost to you
